Healthcare Roundup – Intuitive Surgical earns mixed reviews from analysts despite earnings beat; Amyris acquires Terasana Brand for offering clean cannabinoid consumer products

Published on: January 22, 2021
Author: Amy Liu

Intuitive Surgical earns mixed reviews from analysts despite earnings beat

Notwithstanding the revenue and earnings for Q4 2020 beating the consensus, Intuitive Surgical (NASDAQ:ISRG) is down ~5.2% today after getting mixed views on wall street.

Raymond James reiterates the outperform rating on the stock, raising the price target to $865 from $860.

With COVID-related uncertainty mostly affecting Q1 in 2021, the analyst Lawrence Keusch expects the consensus estimates for Q1 2021 to trend lower in line with management remarks highlighting the pressure on procedures as virus cases surge in the U.S. and Europe.

Predicting a better control over pandemic by the time Q1 results are out, Keusch is uncertain over a much of an impact from Q1 as the analyst expects ‘consistent improvements throughout the year’ afterward to support the positive outlook.

Meanwhile, SVB Leerink analyst Richard Newitter urges clients to look for a better entry point for the stock with the near-term uncertainty over hospital capex and procedure growth rebound limiting the upside potential.

Citing the ‘worries attached to ISRG’s extended rally,’ Seeking Alpha contributor Nikolaos Sismanis in a recent neutral thesis on the stock wrote that company’s ‘current investors have a reduced margin of safety.’

Amyris acquires Terasana Brand for offering clean cannabinoid consumer products

Through the launch of new range of Terasana branded clean beauty products which are focused on sustainably sourced natural cannabinoids, Amyris (NASDAQ:AMRS) will expand its portfolio of consumer brands; stock trading 4.4% higher in premarket.

Amyris will focus on offering leading skincare applications formulated with unique natural cannabinoids that deliver high efficacy sustainable products direct to consumers.

“During Q4 we sold out our entire first industrial production of clean CBG as an ingredient for use in flavors and fragrances. We are very optimistic about the future of clean cannabinoids and the efficacy they can bring to skincare as a logical extension to our existing consumer portfolio. Amyris’s consumer business is nearly half of total product revenue and represents the fastest growing business activity in our portfolio,” president & CEO John Melo commented.

Boston Scientific Wins FDA Approval of Vercise Genus Deep Brain Stimulation System

Boston Scientific Corp. (NYSE:BSX) receives approval for Vercise Genus Deep Brain Stimulation System to treat Parkinson’s disease.

The fourth-generation system delivers electrical stimulation via surgically-implanted leads in the brain connected to an implanted pulse generator

The Verus Genus portfolio, which is conditionally approved in a magnetic resonance imaging environment, includes Bluetooth-enabled, rechargeable and non-rechargeable implanted pulse generators that power Cartesia Directional Leads.

80% of deep brain stimulation systems currently in use in the world are non-rechargeable.

COVID-19 Genomics Healthcare Services Life Science